ZyVersa highlights review article on inflammasome-induced inflammation

ZyVersa Therapeutics (ZVSA) highlights data from a review article published in the peer-reviewed journal, Life. The article summarizes data from 345 publications on the role of inflammasome-induced inflammation in obesity and its comorbidities, and it reinforces the need for therapeutic options to better address the inflammation. “Strong evidence that obesity treatment needs to go beyond weight loss and address the damaging inflammation leading to life-altering comorbidities is driving ZyVersa and other biopharma companies to invest in development of drugs to be used along with incretin therapy to treat inflammation,” said Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “Studies documenting the key role of inflammasomes in triggering obesity-associated inflammation led ZyVersa to focus on this area for development of Inflammasome ASC Inhibitor IC 100. We are excited about the potential of IC 100 to effectively control the inflammation of obesity. Unlike the NLRP3 inhibitors in development, IC 100 targets ASC to inhibit multiple inflammasomes, including NLRP3 and AIM2, which are associated with obesity. More importantly, IC 100 uniquely disrupts the function of ASC specks to attenuate chronic, systemic inflammation leading to obesity comorbidities. We look forward to progressing IC 100’s obesity development program into phase 1 around mid-2025.” In the review article titled, The Interplay between Obesity and Inflammation, the authors concluded: Development of adipose tissue inflammation triggers subsequent cardiovascular events and therefore represents a major reason for the treatment of obesity. The interplay between obesity and inflammation is complex, involving a variety of cellular and humoral factors, and due to the complexity and particular features of the adipose tissue, the inflammation within may persist for long periods of time. Macrophages are the main cellular component driving adipose tissue chronic inflammation. Modulation of macrophages and their release of proinflammatory cytokines, such as NLRP3-driven IL-Ibeta and IL-18, can be a key factor in medical intervention in obese patients. Understanding the pathophysiological changes in adipose tissue and the interplay with chronic inflammation can assist in the design of future studies and reveal opportunities for the development of more efficient therapies for obesity.